We describe a case of A 73-year-old woman, receiving regular blood transfusion for 2 years as affected by myelodysplasia and under treatment with deferasirox (14 mg/kg daily; 2 tablets of 360 mg/die) in the last 2 months due to the registration of high levels of ferritin (1000 µg/L) was admitted because of acute heart failure. She was on treatment only with deferasirox and previously the patient presented normal ECG and at echocardiogram normal cardiac parameters with a left ventricular (LV) ejection fraction of 64%.
Hypersensitivity myocarditis following deferasirox administration / Frustaci, Andrea; Verardo, Romina; Labbadia, Giancarlo; Menafra, Vito; Galea, Nicola; Antonio Russo, Matteo. - In: CIRCULATION. CARDIOVASCULAR IMAGING. - ISSN 1941-9651. - 15:2(2022). [10.1161/CIRCIMAGING.121.013702]
Hypersensitivity myocarditis following deferasirox administration
Frustaci, Andrea
Primo
;Verardo, RominaSecondo
;Labbadia, Giancarlo;Menafra, Vito;Galea, NicolaPenultimo
;Antonio Russo, MatteoUltimo
2022
Abstract
We describe a case of A 73-year-old woman, receiving regular blood transfusion for 2 years as affected by myelodysplasia and under treatment with deferasirox (14 mg/kg daily; 2 tablets of 360 mg/die) in the last 2 months due to the registration of high levels of ferritin (1000 µg/L) was admitted because of acute heart failure. She was on treatment only with deferasirox and previously the patient presented normal ECG and at echocardiogram normal cardiac parameters with a left ventricular (LV) ejection fraction of 64%.| File | Dimensione | Formato | |
|---|---|---|---|
|
Frustaci_Hypersensitivity myocarditis_2022.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
315.68 kB
Formato
Adobe PDF
|
315.68 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
